Dr rita levi montalcini12/3/2023 ![]() Send in your topic request, story ideas, or questions to our gmail or DM us on our social media! If you haven't already, subscribe and leave us a review on Apple Podcasts, Spotify, Buzzsprout, Stitcher, or wherever you like to listen. ![]() ![]() ![]() If she were alive today she'd be someone who never wore a dress without pockets. A survivor, scientist, researcher, and an all around badass. Pharma Nutrition (2013), j.phanu.2013.11.In this episode, Syd covers the fascinating story of Dr. Palmitoylethanolamide (PEA)-promiscuous anti-inflammatory and analgesic molecule at the interface between nutrition and pharma. Keppel Hesselink JMK, Kopsky DJ, Witkamp RF. Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic Compound. Non-neuronal cells therefore, such as glia and mast cells, need much more attention and the above review is an important milestone to treat the myopic focus on neurons alone. Neuropathic pain most probably is much more 'Gliopathic pain' than we ever thought. One could even state that 'Proof of Concept' of glia as an important new target for treating chronic pain has been substantiated by the various clinical trials were PEA was tested in a variety of neuropathic pain states, for instance in nerve compression syndromes (sciatic pain, carpal tunnel syndrome), diabetic neuropathic pain, and pain and loss of function after chemotherapy. PEA's modulating effects on glia most probably is dependent on its affinity for the PPAR receptors, although PEA is a real pleiotropic molecule, as we discussed in some detail, and I am so bold to add two references of my papers related to these topics. PEA is an endogenous modulator and restores active mast cells into resting phenotypes again. It was the great Nobel laureate professor Rita Levi-Montalcini who first discovered PEA's mechanism of action in 1993 related to overactive mast cells. If we conduct a simple Pubmed search based on 'palmitoylethanolamide glia' we find 25 papers. There are many preclinical and clinical trials supporting PEA's efficacy and safety. The more so, as the safety profile of the compound is impressive and no drug-drug interactions have been described. It is freely available in Europe as a food supplement in a capsules of 400 mg and thus one could very well state that palmitoylethanolamide is the first glia-modulator fit for prescribing. Palmitoylethanolamide (PEA) has been explored since its first description in 1957 and found to be a clinically relevant inhibitor of inflammation and an analgesic compound. I miss in their elaborate review all references to palmitoylethanolamide, a natural, endogenous lipid messenger and glia modulator. The history of glia is nicely described in a number of papers, and summarized on In a the textbook 'Lehrbuch der Histologie' from Szymonowicz (1925) the secretory functions of glia are already highlighted, based on the work of Nageotte and Collin. The history of our insights in the functions of glia is extremely interesting. Here they mention Nissl as first author to describe glia in 1899, while in general Virchow is regarded to have described glia already in 1856 as nervous glue: 'Nervenkit.' In their introduction they give a short history of the emergence of insight in glia and its functions. The important and brilliant review of Cherry and colleagues highlights the various modifications of microglia and the complex functionality related to the various phenotypes. Jan keppel hesselink, institute neuropathic pain
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |